Clinical Trials Browser

Completed × Lymphoma, Mantle-Cell × umbralisib × Clear all

NCT02268851 2024-11-15

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Phase 1 Completed

45 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell